Breaking News Instant updates and real-time market news.

TGTX

TG Therapeutics

$6.05

0.15 (2.54%)

08:49
11/22/16
11/22
08:49
11/22/16
08:49

TG Therapeutics says DSMB recommends continuation of UNITY-CLL Phase 3 trial

TG Therapeutics announced that the independent Data Safety Monitoring Board, or DSMB, providing oversight for the UNITY-CLL Phase 3 trial reviewed the cumulative safety data from the ongoing clinical study and informed the company that it has identified no safety concerns, and recommended the continuation of the study with no modifications. Per the protocol's pre-specified DSMB charter, the DSMB is scheduled to meet approximately every 6-9 months to review cumulative safety data. "We are encouraged by the positive outcome of the first DSMB safety review, especially since over two-thirds of the patients currently enrolled in the study are treatment naive CLL patients. Many may recall, as reported by Dr. Jennifer Brown at last year's ASH meeting, and published earlier this year in Blood, that idelalisib in treatment naive CLL patients was observed to cause rapid (most within less than5 weeks) and profound (Grade 3/4) liver toxicity in approximately 50% of the patients treated. Given those findings, we are pleased to report that the DSMB did not find any safety concerns and recommended the study continue without modification. We are also excited to report that the UNITY-CLL study continues to enroll well and we are still targeting completion of enrollment in the first half of 2018," stated Executive Chairman and Interim CEO Michael Weiss.

  • 03

    Dec

TGTX TG Therapeutics
$6.05

0.15 (2.54%)

05/27/16
RHCO
05/27/16
INITIATION
Target $18
RHCO
Buy
TG Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Yatin Suneja initiated TG Therapeutics with a Buy rating and $18 price target.
10/06/16
BMUR
10/06/16
INITIATION
Target $28
BMUR
Buy
TG Therapeutics assumed coverage with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage on TG Therapeutics with a Buy and $28 price target.
10/13/16
ROTH
10/13/16
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains a buyer of TG Therapeutics after GENUINE announcement
After TG Therapeutics announced that it amended the Phase 3 GENUINE study to have overall response rate as the primary endpoint, Roth Capital analyst Joseph Pantginis says the company is making the hard but right decision. While perceptions are negative on trial amendments, the analyst believes this clarity on timelines, the robustness of Phase 2 data and important drug approval precedents continue to point to a positive outcome for the study. Pantginis believes TG Therapeutics' shares are being oversold, and reiterates a Buy rating and $33 price target on the stock. In late morning trading, shares of TG Therapeutics have dropped more than 14% to $7.07.
10/14/16
HCWC
10/14/16
NO CHANGE
Target $18
HCWC
Buy
TG Therapeutics study changes should be no surprise, says H.C. Wainwright
In a research note titled "The Best Way to Pull Off a Band Aid Is Quickly," H.C. Wainwright analyst Andrew Fein says the changes TG Therapeutics announced yesterday to the GENUINE study were "necessary, timely, and, generally, should have not been a surprise" based on the last two quarterly updates. The protocol changes effectively dissolve the Special Protocol Agreement covering the study, which does increase the perceived regulatory risk even upon a study win, Fein tells investors in a research note. He lowered his price target for TG shares to $18 from $22 and keeps a Buy rating on the name. The analyst notes that removing the GENUINE program from his valuation would lead to a $16 price target.

TODAY'S FREE FLY STORIES

MA

MasterCard

$110.74

1.3 (1.19%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Hot Stocks
MasterCard to integrate Masterpass into Gulf Oil's Gulf Pay »

Mastercard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

VALE

Vale

$10.75

-0.49 (-4.36%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Options
Vale put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SATS

EchoStar

$55.24

-0.29 (-0.52%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Earnings
EchoStar reports Q4 EPS 40c, consensus 38c »

Reports Q4 revenue $740M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$46.78

-1.87 (-3.84%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Hot Stocks
Flowserve names Jay Roueche interim CEO, effective immediately »

Flowserve Corporation,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$10.75

-0.49 (-4.36%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Periodicals
Breaking Periodicals news story on Vale »

Vale CEO Ferreira to step…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Apple analyst commentary  »

Apple average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SPLK

Splunk

$64.90

-0.08 (-0.12%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Splunk analyst commentary  »

Splunk should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:48
02/24/17
02/24
07:48
02/24/17
07:48
Hot Stocks
Pearson to rebase dividend from 2017 onwards »

Pearson said: " As…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSO

Pearson

$8.10

0.22 (2.79%)

07:47
02/24/17
02/24
07:47
02/24/17
07:47
Earnings
Pearson backs 2017 outlook, says early trading in line with expectations »

Pearson said its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.